Gapping down
In reaction to disappointing earnings/guidance: CMGE -0.4%, JKS -0.3%
M&A news: TI -2.2% (plans to bid for Vivendi (VIVHY)'s GVT for EUR 7 bln, according to reports), VRX -2% (extends exchange offer to acquire all of the outstanding shares of Allergan (AGN) to December 31, 2014), DLTR -1.3% (in response to FDO/DG news).
Analyst comments: INVN -2.8% (downgraded to Neutral from Buy at Goldman), NXPI -2.3% (downgraded to Sell from Neutral at Goldman), WERN -2.3% (downgraded to Underperform from Neutral at BofA/Merrill), MNST -0.9% (downgraded to Hold from Buy at Jefferies), WCG -0.9% (downgraded to Neutral from Outperform at Wedbush), MXIM -0.9% (removed from Conviction Buy list at Goldman).
In reaction to disappointing earnings/guidance: CMGE -0.4%, JKS -0.3%
M&A news: TI -2.2% (plans to bid for Vivendi (VIVHY)'s GVT for EUR 7 bln, according to reports), VRX -2% (extends exchange offer to acquire all of the outstanding shares of Allergan (AGN) to December 31, 2014), DLTR -1.3% (in response to FDO/DG news).
Analyst comments: INVN -2.8% (downgraded to Neutral from Buy at Goldman), NXPI -2.3% (downgraded to Sell from Neutral at Goldman), WERN -2.3% (downgraded to Underperform from Neutral at BofA/Merrill), MNST -0.9% (downgraded to Hold from Buy at Jefferies), WCG -0.9% (downgraded to Neutral from Outperform at Wedbush), MXIM -0.9% (removed from Conviction Buy list at Goldman).